RheumaGen
PrivateLast Round
Series A
Extension
Dec 22, 2025
Total Funding Raised
$17.25M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
RheumaGen operates in Healthcare & Life Sciences and is based in Aurora, Colorado. Its latest recorded funding round was a Series A Extension round in December 2025.
RheumaGen is a biotechnology company that develops curative cell and gene therapies for autoimmune diseases by editing the human leukocyte antigen (HLA) gene.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
RheumaGen Comparables
Compare RheumaGen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mozart Therapeutics | 74% | |
| GentiBio | 73% | |
| Quell Therapeutics | 72% |
For institutional investors. Book with your work email.
RheumaGen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Dec 22, 2025 | ||||
| Series A | Jan 9, 2025 | ||||
| Grant | Nov 16, 2023 | ||||
| Seed | Oct 12, 2022 | ||||
| Grant | Jan 19, 2022 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
RheumaGen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DCVC Bio | Series A |
| SPRIM Global Investments | Series A |
| Northpond Ventures | Series A |
| Beyond Celiac Investments | Series A Extension |
| F-Prime Capital | Series A |
| SPRIM Global Investments | Series A |
| Colorado Office of Economic Development and International Trade | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 22, 2025
Led by Beyond Celiac Investments
- Oct 7, 2025
Partnering with SiVEC Biotechnologies on gene-editing therapies for autoimmune diseases.
For institutional investors. Book with your work email.
RheumaGen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about RheumaGen's valuation, stock price, and market status.
Is RheumaGen a public or private company?
RheumaGen is a private company.
What is the current stock price of RheumaGen?
RheumaGen is a private company, so its shares have no public market price. Caplight tracks RheumaGen's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is RheumaGen worth (valuation)?
Valuation information for RheumaGen is not publicly available.
Can I buy RheumaGen stock?
RheumaGen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was RheumaGen's last funding round?
RheumaGen's most recent funding round was Series A Extension on December 22, 2025.
Who are the main investors in RheumaGen?
Key investors in RheumaGen include DCVC Bio, SPRIM Global Investments, Northpond Ventures, Beyond Celiac Investments, SPRIM Global Investments.
Will RheumaGen IPO soon?
No public IPO plans have been announced for RheumaGen.
How can I track RheumaGen secondary market activity?
Caplight tracks bids, offers, and trades in RheumaGen's shares on secondary markets.